Article(id=1322906740387357011, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322887634511314961, articleNumber=null, orderNo=null, doi=null, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=1610208000000, acceptedDateStr=2021-01-10, onlineDate=1793335145326, onlineDateStr=2026-10-30, pubDate=1632931200000, pubDateStr=2021-09-30, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793335145326, onlineIssueDateStr=2026-10-30, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793335145326, creator=13701087609, updateTime=1793335145326, updator=13701087609, issue=Issue{id=1322887634511314961, tenantId=1146029695717560320, journalId=1235980733773295621, year='2021', volume='30', issue='18', pageStart='1633', pageEnd='1728', issueExtLink='null', onlineDate='null', pubDate='1632931200000', pubDateStr='2021-09-30', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793330590131, creator='13701087609', updateTime=1793337355310, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1322916009916629692, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322887634511314961, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1322916009916629693, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322887634511314961, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1638, endPage=1641, ext={EN=ArticleExt(id=1322906740559323476, articleId=1322906740387357011, tenantId=1146029695717560320, journalId=1235980733773295621, language=EN, title=An anti-CD19 CAR-T cell drug for mantle cell lymphoma: brexucabtagene autoleucel, columnId=null, journalTitle=Chinese Journal of New Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Brexucabtagene autoleucel (Bre-cel) is an anti-CD19 chimeric antigen receptor (CAR)-T cell drug, developed by Kite Pharmaceuticals. Bre-cel (Tecartus) was approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) by the U.S. Food and Drug Administration on July 24th, 2020. Bre-cel is the first drug of CAR-T cell gene therapy for MCL. This review summarizes the pharmacological effect, pharmacokinetics, clinical trials and safety of Bre-cel.

, authors=Kong-lang XING, Fang CHAI, authorsList=Kong-lang XING, Fang CHAI, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1322906740945199445, articleId=1322906740387357011, tenantId=1146029695717560320, journalId=1235980733773295621, language=CN, title=治疗套细胞淋巴瘤的抗CD19 CAR-T细胞药物brexucabtagene autoleucel, columnId=1236331162679955859, journalTitle=中国新药杂志, columnName=新药述评与论坛, runingTitle=null, highlight=null, articleAbstract=

Brexucabtagene autoleucel（简称Bre-cel，商品名：Tecartus）是一种由凯特制药公司（Kite Pharmaceuticals）开发的抗CD19嵌合抗原受体（chimeric antigen receptor，CAR）-T细胞药物。2020年7月24日，美国FDA通过加速审评程序，批准其用于治疗复发或难治性套细胞淋巴瘤的成人患者。Bre-cel是首款针对套细胞淋巴瘤基因治疗的CAR-T细胞药物。本文主要对其作用机制、药动学、临床研究及安全性进行概述。

, authors=邢孔浪, 柴芳, authorsList=邢孔浪, 柴芳, authorCompany=null, correspAuthors=null, authorNote=, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=《中国新药杂志》有限公司, extLink=null, articleAbsUrl=null, sourceXml=xj5lzKHGTsfNwKrQwjCNAA==, magXml=fWUy0eb+ZdQIwP5uzvOldw==, pdfUrl=null, pdf=meZ16JHw/1FRySjgKsXMCw==, pdfFileSize=1051474, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=bE02+2MN9MTlCmdUV8SdXg==, mapNumber=null, fund=null)}, authors=[Author(id=1322906741284938074, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=394332409@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906741368824156, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, authorId=1322906741284938074, language=EN, stringName=Kong-lang XING, firstName=Kong-lang, middleName=null, lastName=XING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, Sanya People's Hospital, Sanya 572000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906743046545758, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, authorId=1322906741284938074, language=CN, stringName=邢孔浪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=三亚市人民医院药学部，三亚　572000, bio={"content":"

邢孔浪，男，主管药师，主要从事临床药学工作。联系电话：（0898）88021145，E-mail：394332409@qq.com。

"}, bioImg=null, bioContent=

邢孔浪，男，主管药师，主要从事临床药学工作。联系电话：（0898）88021145，E-mail：394332409@qq.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906741192663382, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, xref=null, ext=[AuthorCompanyExt(id=1322906741201051991, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, companyId=1322906741192663382, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, Sanya People's Hospital, Sanya 572000, China), AuthorCompanyExt(id=1322906741213634904, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, companyId=1322906741192663382, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=三亚市人民医院药学部，三亚　572000)])]), Author(id=1322906743277232480, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906743369507170, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, authorId=1322906743277232480, language=EN, stringName=Fang CHAI, firstName=Fang, middleName=null, lastName=CHAI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, Sanya People's Hospital, Sanya 572000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906743474364771, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, authorId=1322906743277232480, language=CN, stringName=柴芳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=三亚市人民医院药学部，三亚　572000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906741192663382, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, xref=null, ext=[AuthorCompanyExt(id=1322906741201051991, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, companyId=1322906741192663382, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, Sanya People's Hospital, Sanya 572000, China), AuthorCompanyExt(id=1322906741213634904, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, companyId=1322906741192663382, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=三亚市人民医院药学部，三亚　572000)])])], keywords=[Keyword(id=1322906743587610980, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, language=EN, orderNo=1, keyword=brexucabtagene autoleucel (Bre-cel)), Keyword(id=1322906743663108453, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, language=EN, orderNo=2, keyword=mantle-cell lymphoma (MCL)), Keyword(id=1322906743738605926, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, language=EN, orderNo=3, keyword=CD19), Keyword(id=1322906743814103399, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, language=EN, orderNo=4, keyword=clinical trials), Keyword(id=1322906743893795176, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, language=CN, orderNo=1, keyword=brexucabtagene autoleucel), Keyword(id=1322906744019624297, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, language=CN, orderNo=2, keyword=套细胞淋巴瘤), Keyword(id=1322906744116093290, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, language=CN, orderNo=3, keyword=CD19), Keyword(id=1322906744174813547, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, language=CN, orderNo=4, keyword=临床研究)], refs=[Reference(id=1322906744275476844, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=HANEL W, EPPERLA N. Cancer, Mantle Cell Lymphoma[EB/OL]. (2020-06-07) [2020-07-26]. https://www.ncbi.nlm.nih.gov/books/NBK536985/., articleTitle=null, refAbstract=null), Reference(id=1322906744350974317, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=JAIN P, WANG M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management[J]. Am J Hematol, 2019, 94(6): 710-725., articleTitle=null, refAbstract=null), Reference(id=1322906744422277486, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=OWEN C, BERINSTEIN NL, CHRISTOFIDES A, et al. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma[J]. Curr Oncol, 2019, 26(2): e233-e240., articleTitle=null, refAbstract=null), Reference(id=1322906744510357871, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=王姝, 黄文海, 沈正荣. 布鲁顿酪氨酸激酶靶向药物的研究进展[J]. 中国现代应用药学, 2020, 37(24): 3063-3072., articleTitle=null, refAbstract=null), Reference(id=1322906744602632560, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=边妍, 郑志华, 罗思宇, 等. 伊布替尼治疗CLL/SLL、MCL的快速卫生技术评估[J]. 今日药学, 2021, 31(8): 587-591., articleTitle=null, refAbstract=null), Reference(id=1322906744686518641, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=ROBINSON SP, BOUMENDIL A, FINEL H, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party[J]. Bone Marrow Transplant, 2018, 53(5): 617-624., articleTitle=null, refAbstract=null), Reference(id=1322906744782987634, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome[EB/OL]. (2017-08-30) [2020-07-29]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome., articleTitle=null, refAbstract=null), Reference(id=1322906744862679411, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma[EB/OL]. (2017-10-18) [2020-07-29]. https://www.fda.gov/news-events/press-announcements/fda-approves-CAR-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma., articleTitle=null, refAbstract=null), Reference(id=1322906744942371188, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=汪龙, 王慕华, 张莉, 等. 治疗B细胞淋巴瘤的抗CD19 CAR-T细胞药物: axicabtagene ciloleucel[J]. 中国新药与临床杂志, 2018, 37(10): 544-548., articleTitle=null, refAbstract=null), Reference(id=1322906745017868661, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=POOREBRAHIM M, SADEGHI S, FAKHR E, et al. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects[J]. Crit Rev Clin Lab Sci, 2019, 56(6): 393-419., articleTitle=null, refAbstract=null), Reference(id=1322906745080783222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma[EB/OL]. (2020-07-24) [2020-07-31]. https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma., articleTitle=null, refAbstract=null), Reference(id=1322906745164669303, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. FDA approves first cell-based gene therapy for adult patients with relapsed or refractory MCL[EB/OL]. (2020-07-24) [2020-07-31]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-relapsed-or-refractory-mcl., articleTitle=null, refAbstract=null), Reference(id=1322906745240166776, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=陆忆娟, 马爱霞. CAR-T细胞免疫疗法治疗血液恶性肿瘤系统综述[J]. 中国新药杂志, 2020, 29(5): 534-540., articleTitle=null, refAbstract=null), Reference(id=1322906745370190201, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=FEINS S, KONG W, WILLIAMS EF, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer[J]. Am J Hematol, 2019, 94(S1): S3-S9., articleTitle=null, refAbstract=null), Reference(id=1322906745462464890, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=SALTER AI, PONT MJ, RIDDELL SR. Chimeric antigen receptor-modified T cells: CD19 and the road beyond[J]. Blood, 2018, 131(24): 2621-2629., articleTitle=null, refAbstract=null), Reference(id=1322906745667985787, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=KOCHENDERFER JN, ROSENBERG SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors[J]. Nat Rev Clin Oncol, 2013, 10(5): 267-276., articleTitle=null, refAbstract=null), Reference(id=1322906745818980732, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. Tecartus^®(brexucabtagene autoleucel) suspension for intravenous infusion[EB/OL]. (2020-07-24) [2020-08-03]. https://www.fda.gov/media/140409/download., articleTitle=null, refAbstract=null), Reference(id=1322906745907061118, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=KOCHENDERFER JN, SOMERVILLE RPT, LU T, et al. Lymphoma remissions caused by Anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels[J]. J Clin Oncol, 2017, 35(16): 1803-1813., articleTitle=null, refAbstract=null), Reference(id=1322906747568005503, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG M, MUNOZ J, GOY A, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma[J]. N Engl J Med, 2020, 382(14): 1331-1342., articleTitle=null, refAbstract=null), Reference(id=1322906747664474496, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=DRUGS.COM. Tecartus[EB/OL]. (2020-07-24) [2020-08-05]. https://www.drugs.com/tecartus.html., articleTitle=null, refAbstract=null), Reference(id=1322906747752554881, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=屈哲, 林志, 吕建军, 等. CAR-T细胞产品毒性评价概述[J]. 中国新药杂志, 2019, 28(21): 2646-2650., articleTitle=null, refAbstract=null), Reference(id=1322906747832246658, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=NEELAPU SS, LOCKE FL, BARTLETT NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma[J]. N Engl J Med, 2017, 377(26): 2531-2544., articleTitle=null, refAbstract=null), Reference(id=1322906747907744131, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=LOCKE FL, NEELAPU SS, BARTLETT NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma[J]. Mol Ther, 2017, 25(1): 285-295., articleTitle=null, refAbstract=null), Reference(id=1322906747991630212, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=WIERDA WG, BISHOP MR, OLUWOLE O, et al. Updated phase 1 results of Zuma-3: Kte-X19, an Anti-CD19 chimeric antigen receptor T cell therapy, in adult patients with relapsed/refractory acute lymphoblastic leukemia[J]. Biol Blood Marrow Transplant, 2019, 25(3): S185., articleTitle=null, refAbstract=null), Reference(id=1322906748075516293, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=NIH. A phase 2 multicenter study evaluating subjects with relapsed/refractory mantle cell lymphoma (ZUMA-2)[EB/OL]. (2020-07-21) [2020-08-06]. https://clinicaltrials.gov/ct2/show/NCT02601313?term=NCT02601313&draw=2&rank=1., articleTitle=null, refAbstract=null), Reference(id=1322906748146819462, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=DRUGS.COM. FDA approves Tecartus[EB/OL]. (2020-07-24) [2020-08-08]. https://www.drugs.com/newdrugs/fda-approves-tecartus-brexucabtagene-autoleucel-first-only-CAR-t-relapsed-refractory-mantle-cell-5304.html., articleTitle=null, refAbstract=null), Reference(id=1322906748213928327, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=KITE. U.S. FDA approves Kite's Tecartus^TM, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma[EB/OL]. (2020-07-25) [2020-08-08]. https://www.kitepharma.com/news/press-releases/2020/7/us-fda-approves-kites-tecartus-the-first-and-only-CAR-t-treatment-for-relapsed-or-refractory-mantle-cell-lymphoma., articleTitle=null, refAbstract=null), Reference(id=1322906748293620104, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=NIH. Safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (ZUMA-8)[EB/OL]. (2020-07-24) [2020-08-10]. https://clinicaltrials.gov/ct2/show/NCT03624036?term=KTE-X19&draw=2&rank=1., articleTitle=null, refAbstract=null), Reference(id=1322906748394283401, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=NIH. A study evaluating KTE-X19 in adult subjects with relapsed/refractory b-precursor acute lymphoblastic leukemia (ZUMA-3)[EB/OL]. (2020-06-09) [2020-08-10]. https://clinicaltrials.gov/ct2/show/NCT02614066?term=KTE-X19&draw=2&rank=2., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1322906741192663382, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, xref=null, ext=[AuthorCompanyExt(id=1322906741201051991, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, companyId=1322906741192663382, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, Sanya People's Hospital, Sanya 572000, China), AuthorCompanyExt(id=1322906741213634904, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906740387357011, companyId=1322906741192663382, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=三亚市人民医院药学部，三亚　572000)])], figs=null, attaches=null, journal=Journal(id=1235980159023624194, delFlag=0, nameCn=中国新药杂志, nameEn=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, issn=1003-3734, eissn=null, cn=11-2850/R, coden=ZXZHA6, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs, journalRemark=null, publicationField=null, createdTime=1772610233314, updatedTime=1788948968376, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=ohPEEN//Vz1tDT3ZBNTp4Q==, picEn=f9WK9bvTM4guTmS/iGhOMg==, jcr=null, cjcr=null, exts=[JournalExt(id=1304509780974924039, language=CN, name=中国新药杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968404, updatedTime=1788948968404, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1304509781025255688, language=EN, name=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968416, updatedTime=1788948968416, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1235980733773295621, websiteList=[Website(id=1235982099191222761, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/CN, language=CN, createTime=1772610695884, createBy=18614031015, updateTime=1772610860397, updateBy=18614031015, name=中国新药杂志-中文, tplId=1146099689490845704, title=中国新药杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983918629966444, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=articleTextType, value=kx, createTime=1772611129672, updateTime=1772611129672, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918604800617, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=banner, value=null, createTime=1772611129666, updateTime=1772611129666, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918655132271, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=grayFlag, value=0, createTime=1772611129678, updateTime=1772611129678, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918596412008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611129664, updateTime=1772611129664, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918667715185, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=minRunFlag, value=0, createTime=1772611129681, updateTime=1772611129681, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918617383531, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic, createTime=1772611129669, updateTime=1772611129669, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918659326576, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=silenceFlag, value=0, createTime=1772611129679, updateTime=1772611129679, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918613189226, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1772611129668, updateTime=1772611129668, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918634160749, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeColor, value=null, createTime=1772611129673, updateTime=1772611129673, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918646743662, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeStyle, value=null, createTime=1772611129676, updateTime=1772611129676, creator=18614031015, updator=18614031015)]), Website(id=1235982099270914542, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/EN, language=EN, createTime=1772610695903, createBy=18614031015, updateTime=1772610875891, updateBy=18614031015, name=中国新药杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983955829248630, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=articleTextType, value=kx, createTime=1772611138541, updateTime=1772611138541, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955804082803, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=banner, value=null, createTime=1772611138535, updateTime=1772611138535, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955854414457, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=grayFlag, value=0, createTime=1772611138547, updateTime=1772611138547, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955795694194, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611138533, updateTime=1772611138533, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955866997371, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=minRunFlag, value=0, createTime=1772611138550, updateTime=1772611138550, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955820860021, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic, createTime=1772611138539, updateTime=1772611138539, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955862803066, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=silenceFlag, value=0, createTime=1772611138549, updateTime=1772611138549, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955812471412, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1772611138537, updateTime=1772611138537, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955837637239, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeColor, value=null, createTime=1772611138543, updateTime=1772611138543, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955846025848, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeStyle, value=null, createTime=1772611138545, updateTime=1772611138545, creator=18614031015, updator=18614031015)])], journalTitle=中国新药杂志, weixinUrl=null, journalUrl=http://www.newdrug.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs, journalPhotoCn=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPhotoEn=f9WK9bvTM4guTmS/iGhOMg==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/Y2021/V30/I18/1638, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/Y2021/V30/I18/1638, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/PDF/Y2021/V30/I18/1638, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/PDF/Y2021/V30/I18/1638, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1632931200000, fullTextJson=null, articleText=null, reference=null)